Neumora Therapeutics, Inc. $NMRA Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP increased its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 392.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 534,044 shares of the company’s stock after acquiring an additional 425,633 shares during the period. GSA Capital Partners LLP’s holdings in Neumora Therapeutics were worth $956,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC raised its holdings in Neumora Therapeutics by 63.1% during the third quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock worth $3,655,000 after purchasing an additional 776,856 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Neumora Therapeutics during the third quarter worth $1,512,000. AlphaCore Capital LLC raised its holdings in Neumora Therapeutics by 89.1% during the third quarter. AlphaCore Capital LLC now owns 638,784 shares of the company’s stock worth $1,163,000 after purchasing an additional 301,017 shares during the last quarter. AQR Capital Management LLC acquired a new position in Neumora Therapeutics during the first quarter worth $463,000. Finally, Cerity Partners LLC raised its holdings in Neumora Therapeutics by 7.2% during the second quarter. Cerity Partners LLC now owns 324,219 shares of the company’s stock worth $238,000 after purchasing an additional 21,714 shares during the last quarter. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $1.85 on Friday. The firm has a market capitalization of $342.77 million, a P/E ratio of -1.39 and a beta of 3.02. The stock has a fifty day moving average price of $2.20 and a 200 day moving average price of $2.35. Neumora Therapeutics, Inc. has a 52 week low of $0.66 and a 52 week high of $3.65. The company has a current ratio of 5.09, a quick ratio of 5.09 and a debt-to-equity ratio of 0.75.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, May 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. Equities research analysts anticipate that Neumora Therapeutics, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

NMRA has been the subject of a number of analyst reports. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Guggenheim reissued a “buy” rating and issued a $14.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Tuesday, April 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.67.

Neumora Therapeutics Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.